European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases.","authors":"Gokce Belge Bilgin,Cem Bilgin,Brian J Burkett,Matthew P Thorpe,Ann T Packard,Fatma Fidanli,Daniel S Childs,Miguel Muniz,Jacob J Orme,J Fernando Quevedo,Sani H Kizilbash,Eugene D Kwon,Geoffrey B Johnson,Derek R Johnson,Oliver Sartor,Ayse Tuba Kendi","doi":"10.1007/s00259-025-07447-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07447-0","url":null,"abstract":"BACKGROUNDCentral nervous system (CNS) metastases in prostate cancer are rare but pose a significant treatment challenge and are linked to poor prognosis. Data on the outcomes of this specific patient subgroup treated with radioligand therapy (RLT) remain scarce. In this study, we aim to leverage real-world clinical data to evaluate the outcomes of RLT with [177Lu] Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) and CNS metastases.METHODSClinical and imaging data of patients who received their initial dose of [177Lu] Lu-PSMA-617 between March 2022 and April 2024 were retrospectively reviewed. All patients who were known to have at least one parenchymal CNS metastasis confirmed radiologically through dedicated neuroimaging, with or without histopathological confirmation, were included in the study. Central nervous system metastases (CNS) were defined as metastatic lesions involving the cerebrum, cerebellum, or spinal cord. The mCRPC patients with dural metastases but without parenchymal CNS disease were excluded.RESULTSA total of 589 patients underwent RLT with [177Lu] Lu-PSMA-617 for mCRPC, of whom 12 (2%, 12/589) had CNS metastases. Among these, eight patients (67%, 8/12) had pre-existing CNS lesions, while the remaining four patients (33%, 4/12) were diagnosed with CNS metastases after initiating RLT. Patients received no additional systemic or focal therapies concurrently with RLT. The mean follow-up period was 5.7 ± 6.9 months. The median overall survival from the initial dose of RLT was 4.5 months (range: 1.1-29.87 months). Among eight patients with pre-existing CNS metastases, CNS lesions resolved completely or nearly completely in three patients (37.5%, 3/8), while two patients (25%, 2/8) exhibited a mixed response, and three patients (37.5%, 3/8) experienced CNS disease progression following RLT. Among four patients diagnosed with CNS metastases after initiating therapy, three patients (75%, 3/4) experienced a rapid clinical decline necessitating urgent intervention, while the remaining patient (25%, 1/4) responded well to the therapy without developing new or worsening neurological symptoms. None of the patients were able to complete the full six cycles of RLT, with discontinuation mainly due to overall disease progression or infection-related complications.CONCLUSIONSOur study suggests that patients with CNS metastases, whether diagnosed before or after therapy, exhibited a poor prognosis, with a median survival of 4.5 months after initiation of RLT. Although a complete/near-complete radiologic response in the CNS lesions was observed in 25% of the patients, only two patients were able to complete more than three cycles of therapy. Given the small sample size, larger multicenter studies are needed to validate these findings.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"8 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of two preprocessing methods for 18F-Flortaucipir PET quantification in Alzheimer's disease.","authors":"Elif Harput,Debora Elisa Peretti,Max Scheffler,Nicholas J Ashton,Kaj Blennow,Henrik Zetterberg,Ruben Smith,Giovanni B Frisoni,Valentina Garibotto,Cecilia Boccalini","doi":"10.1007/s00259-025-07452-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07452-3","url":null,"abstract":"BACKGROUNDTau-Positron Emission Tomography (PET) has become central in Alzheimer's disease (AD) research and clinical settings. Multiple preprocessing pipelines for tau-PET quantification have been described, with satisfactory performance but direct comparisons remain scarse. Our study evaluates the comparability of two commonly used PET preprocessing methods, respectively in native and standard spaces, in quantifying tau deposition and in their ability to discriminate AD patients.METHODS209 subjects were included from the Geneva memory clinic including cognitively unimpaired (CU) individuals, mild cognitive impairment (MCI) and dementia patients. Images were processed in native and standard space using inferior cerebellar grey matter as reference region. Standardized uptake value ratios (SUVR) were extracted from AD-specific regions. Correlations between SUVR obtained by different methods and plasma biomarkers were assessed. ROC analyses compared the ability of the two methods to discriminate visually assessed tau status, amyloid-positive cognitively impaired from amyloid-negative CU, and subjects with declining cognition over time.RESULTSSUVR from the two methods were strongly correlated across all regions. However, SUVR values obtained with standard space method showed higher values. SUVR in the medial temporal lobe from native space processing provided a greater accuracy in discriminating positive scans and identifying subjects with cognitive decline. For all other analyses methods performed equally well. The correlation with plasma biomarkers was comparably high with both methods.CONCLUSIONWhile preprocessing in native and standard space is adequate for quantifying 18F-Flortaucipir PET and for discriminating AD patients, higher accuracy can be obtained in the mesial temporal regions and to predict cognitive decline using processing in native space.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"24 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival.","authors":"Yizhao Xie,Yifan Chen,Cheng Liu,Yannan Zhao,Chengcheng Gong,Shuyi Lin,Shaoli Song,Biyun Wang,Zhongyi Yang","doi":"10.1007/s00259-025-07459-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07459-w","url":null,"abstract":"BACKGROUNDWhile CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i+ET) have revolutionized treatment for HR+/HER2- metastatic breast cancer (MBC), inter-lesional estrogen receptor (ER) heterogeneity limits therapeutic efficacy in a subset of patients. Whole-body 18F-fluoroestradiol (18F-FES) PET/CT enables non-invasive ER quantification across all metastatic sites. However, whether 18F-FES-guided therapy selection improves clinical outcomes in relatively large sample cohorts is not yet well-established.PATIENTS AND METHODSWe screened all 1613 HR+/HER2- metastatic breast cancer (MBC) patients from 2020 to 2024 at Fudan University Shanghai Cancer Center. Patients who received standard first line treatment were enrolled in this retrospective study.RESULTSA total of 473 patients were included in the study. 156(33.0%) and 317 (67.0%) patients were screened or unscreened by 18F-FES-PET before first-line treatment. 111 patients with all-FES positive metastatic lesions and 17 patients with FES heterogeneity received CDK4/6 inhibitors combined with endocrine therapy. 21 patients with all-FES negative metastatic lesions and 7 patients with FES heterogeneity received chemotherapy (CT). As for the unscreened group, 236 received CDK4/6 inhibitors combined with endocrine therapy and 81 received CT. In CDK4/6 inhibitors combined with endocrine therapy cohort, FES-screened group showed a significantly prolonged progression-free survival (PFS) compared with unscreened group (mPFS 32.4 months versus 17.3 months, Hazard Ratio = 0.49; 95% CI, 0.34 to 0.69; p < 0.0001). And chemotherapy cohort showed superior PFS for screened patients as well (mPFS 11.38 months versus 8.91 months, Hazard Ratio = 0.56; 95% CI, 0.33 to 0.94; p = 0.026).CONCLUSIONSHR + /HER2- MBC patients with FES-guided initial treatment showed significantly better efficacy than those who had not been assessed by 18F-FES-PET/CT. This retrospective study highlights the crucial instructive role of FES assessment in evaluating ER expression in patients prior to administering first-line treatment. In the present study, improved PFS was observed when first-line therapy was guided by 18F-FES-PET in newly diagnosed HR+/HER2- MBC patients.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"672 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental myocardial uptake of 68Ga-FAPI-04 caused by hypertrophic cardiomyopathy in a patient with Immunoglobulin G4-related disease.","authors":"Silu Liu,Jie Feng,Hongzhe Zhang,Qingqing Pan,Yaping Luo","doi":"10.1007/s00259-025-07424-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07424-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"94 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does PARP1 up-regulation correlate with PSMA expression in patients with metastatic castration-resistant prostate cancer studied with [18F]PARPi and [68Ga]PSMA PET/CT?","authors":"Holger Einspieler,Heidemarie Ofner,Marius Ozenil,Clemens P Spielvogel,Ilva Kristiana Langrate,Melanie R Hassler,Lukas Nics,Karsten Bamminger,Pascal A T Baltzer,Shahrokh F Shariat,Marcus Hacker,Gero Kramer,Sazan Rasul","doi":"10.1007/s00259-025-07448-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07448-z","url":null,"abstract":"PURPOSE[18F] Poly-ADP-ribose polymerase inhibitors (PARPi), a novel radiotracer, enables visualization of PARP1 upregulation by PET imaging. Here, we aimed to quantify PARPi uptake in tumor lesions of metastatic castration-resistant PCa (mCRPC) patients and perform a comparison with prostate specific membrane antigen (PSMA) expression using PET/CT scans.METHODSData from 22 male patients with mCRPC, who underwent [18F]PARPi and [68Ga]Ga-PSMA-11 PET/CT scans, were retrospectively quantified. Lesions with relevant PARPi uptake (higher than background) were delineated and correlated with their [68Ga]PSMA uptake using standardized uptake values (SUV). Additionally, a comparison was performed to investigate the effects of homologous recombination deficiency (HRD) alterations on PARPi tumor uptake.RESULTSThe majority of metastatic PCa lesions that exhibited PARPi uptake were located in the bones (n = 57), with mean SUVmax values of 4.9 ± 1.5 for PARPi and 30.9 ± 28.3 for [68Ga]PSMA. Additionally, 3 local prostate lesions, 14 lymph nodes and 4 further metastatic lesions were detected. Significant correlations were identified between PARPi- and [68Ga]PSMA uptake, as measured by SUVmean (r = 0.48, p < 0.001), SUVpeak (r = 0.48, p < 0.001) and SUVmax (r = 0.43, p < 0.001) of the osseous metastatic lesions and SUVpeak (r = 0.49, p = 0.04) of extraosseous lesions. No significant differences were found between PARPi uptake of metastatic lesions in patients with or without HRD alterations (all p > 0.05).CONCLUSIONResults showed a considerable uptake of [18F]PARPi in mCRPC patients and indicated a correlation between PARPi uptake and PSMA expression, suggesting the potential of using [18F]PARPi as a diagnostic imaging tool in mCRPC patients. More studies are needed to evaluate the clinical benefit of this innovative radiotracer.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"267 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DTI-ALPS index-assessed glymphatic dysfunction mediates Alzheimer's cognitive decline via amyloid-β-dependent pathways: multimodal PET/MRI study.","authors":"Yan Zhang,Gan Huang,Jieli Geng,Xia Li,Mei Xin,Peizhe Yuan,Yue Wang,Qun Xu,Gang Wang,Gang Huang,Jianjun Liu,Chenpeng Zhang","doi":"10.1007/s00259-025-07445-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07445-2","url":null,"abstract":"PURPOSEThe role of glymphatic dysfunction in Alzheimer's disease (AD), as measured by diffusion tensor imaging along perivascular spaces (DTI-ALPS) indexing of perivascular function, its progression, and its interaction with amyloid-β (Aβ) and tau proteins, remains controversial. To investigate whether the DTI-ALPS index mediates AD-related cognitive decline through Aβ/tau-dependent pathways using tri-tracer PET/MRI.METHODSThis retrospective study (2021-2024) analyzed 140 participants (median age 69.00 [61.00, 74.00] years; 84 women), including 99 with AD (37 early-onset [EOAD], 62 late-onset [LOAD]), 35 with mild cognitive impairment (MCI), and 6 with subjective cognitive decline (SCD). All participants underwent simultaneous [1⁸F] Florbetapir (Aβ), [1⁸F] PI-2620(tau), and [1⁸F] FDG PET/MRI with DTI-ALPS indexing for glymphatic function quantification. Causal mediation analysis was used to assess the relationships between biomarkers (P < 0.05).RESULTSThe ALPS index progressively decreased across clinical stages (SCD: 1.51 ± 0.08 vs. MCI: 1.37 ± 0.13 vs. AD: 1.32 ± 0.14; P = 0.001), correlating with higher Aβ-PET (r = - 0.31, P < 0.001), tau-PET (ρ = - 0.18, P = 0.035), and FDG-PET scores (ρ = - 0.22, P = 0.008). Aβ-PET fully mediated the ALPS effects on FDG-PET (β = - 0.14, P = 0.002) and cognition (β = 0.12 ~ 0.14, P < 0.01), independent of tau (P > 0.05). The Aβ-negative subgroups showed correlations with ALPS-age (r = - 0.48, P = 0.007), ALPS-education (r = 0.39, P = 0.035), and ALPS-cognition (MoCA: r = 0.62, P < 0.001). The Aβ-positive subgroups revealed inverse ALPS-Aβ associations (ρ = - 0.27, P = 0.010; age/education-adjusted ρ = - 0.24, P = 0.022) alongside positive adjusted correlations with cognition (MMSE: ρ = 0.28, P = 0.009). EOAD exhibited distinct ALPS-cognition relationships compared to LOAD (MMSE: r = - 0.39, P = 0.016 vs. ρ = - 0.06, P = 0.620).CONCLUSIONDTI-ALPS quantifies glymphatic dysfunction driving AD progression predominantly through Aβ-dependent pathways, with EOAD demonstrating distinct neuroimaging-cognition relationships compared to LOAD.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"10 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiopharmaceutical kit to prepare Copper-64 labelled porphyrin-lipid nanoparticles for radiotracer imaging studies in cancer patients.","authors":"Michael S Valic,Carl J Fisher,Mark Zheng,Alexander M Gregor,Wenlei Jiang,Conrad Chan,Harley H L Chan,Abdullah El-Sayes,Chris J Zhang,Tina Ye,Michael Halim,Pamela Schimmer,Celina Li,Nicholas Bernards,Arthur C K Chu,Zhongli Cai,Juan Chen,Jonathan C Irish,Kazuhiro Yasufuku,Robert Weersink,Raymond M Reilly,Brian C Wilson,Gang Zheng","doi":"10.1007/s00259-025-07442-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07442-5","url":null,"abstract":"PURPOSEPORPHYSOMES (PS) are multifunctional porphyrin-lipid nanoparticles for fluorescence-guided photochemical tumour ablation and immune stimulation. PS can be radiolabelled with Copper-64 (64Cu-PS) to permit tracing of their whole-body distribution and uptake in tumours with nuclear imaging. Herein we characterised the physicochemical and radiochemical properties of PS and 64Cu-PS and evaluated their pharmacology and toxicology in rats and dogs.METHODS64Cu-PS labelling procedure was optimised and developed into a \"one pot\" kit format. The plasma pharmacokinetics (PK), tissue distribution, and single and repeat-dose toxicity of dose escalating PS was evaluated after intravenous injection in healthy Fisher 344 rats and Beagle dogs. Radiation dosimetry from single 64Cu-PS dose was estimated in humans.RESULTSKit prepared 64Cu-PS had high labelling yields and mean specific activities of 18.5 MBq/mg (11.4 GBq/mg max). The plasma PK of PS was linear between doses 0.5-15 mg/kg in both rats and dogs. Tissue distribution was primarily to the liver. The estimated effective dose from 64Cu-PS in humans was 38-47 µSv/MBq. Single doses of 32.6 mg/kg PS did not have detectable toxicities in rats. In dogs, mild transient infusion reactions were observed following single and repeat-doses of PS starting at ≥ 10 mg/kg PS. Doses up to 15 mg/kg PS were tolerated in dogs.CONCLUSIONSThe pharmacology and safety profiles of PS and 64Cu-PS in rats and dogs did not raise concerns regarding their use in humans. Radiolabelled 64Cu-PS will permit accurate imaging-based assessments of nanoparticle PK and tumour uptake in imaging studies in cancer patients.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"14 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting PD-L1 expression status in NSCLC using radiomic analysis of 18 F-FDG-PET/CT images.","authors":"Fanni Júlia Kiss,Anna Izabell Járó,Domokos Máthé,Csaba Benedek,Vilmos Madaras,Andrea Manno-Kovács,Árpád László Bartha,Parasuraman Padmanabhan,Ramasamy Paulmurugan,Eszter Regős,Tamás Györke,Krisztián Szigeti","doi":"10.1007/s00259-025-07453-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07453-2","url":null,"abstract":"PURPOSELung cancer is the most prevalent malignancy globally, with prognosis and treatment largely influenced by histological and molecular analyses. Molecular features like PD-L1 positivity help identify patients suitable for immunotherapy. However, obtaining histological samples can be challenging and limited. Radiomic analysis of imaging data provides a non-invasive way to characterize tumor heterogeneity and its complex patterns, which may help predict PD-L1 expression. This study investigates the efficacy of radiomics in forecasting PD-L1 status in NSCLC patients using 18 F-FDG-PET/CT images.METHODSIn this retrospective study, the primary staging 18 F-FDG-PET/CT scans of 105 patients with NSCLC of different phenotypes (72 ACC, 33 SCC, 64 PD-L1 positive, 41 PD-L1 negative) were analysed. Various segmentation techniques were employed. Radiomic features were obtained from the original and transformed images using the PyRadiomics package. Records were split into training and test sets in the ratio of 7:3. Feature reduction involved the Mann-Whitney U test, LASSO regression, and Spearman correlation analysis. A logistic regression model was developed using the selected features, and performance was assessed with ROC curve, AUC score, and other metrics.RESULTSThe optimal model achieved an AUC of 0.783 (95% CI: 0.625, 942), with high accuracy (81.25%), sensitivity (90.00%), PPV (81.81%), and NPV (80.00%).CONCLUSIONRadiomic features derived from 18 F-FDG-PET/CT images can potentially differentiate between PD-L1 positive and negative NSCLC. Consequently, radiomics with multimodal imaging presents a promising non-invasive approach for selecting patients who may benefit from targeted immunotherapy.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"10 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144640018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early image acquisition 68Ga-FAPI-46-PET/CT in prone position is promising in the workup of rectosigmoid and anal carcinoma.","authors":"D Ufton,J Heilinger,H Weis,T Fischer,K Schomäcker,C Bruns,G Dieplinger,H Dapper,E Fokas,C Kobe,A Drzezga,S Ferdinandus,K S Roth","doi":"10.1007/s00259-025-07451-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07451-4","url":null,"abstract":"PURPOSETo overcome difficulties with regard to anatomic discrimination of intrapelvic tumors and non-specific intrapelvic uptake (i.e. excreted activity in the urinary bladder) by early acquisition of FAPI-PET in prone position.METHODS15 patients with rectosigmoid (RSC) and squamous cell carcinoma of the anus (SCCA) underwent early-imaging 68Ga-FAPI-46-PET/CT-scans in prone position 5.9 ± 1.3 min after radiotracer injection. SUV and metric values for primary tumors, metastases, bladder and background tissues were measured. Tumor-to-background ratios (TBR) were calculated.RESULTSDespite early acquisition, SUV was already high in tumors and metastases, leading to high TBR. A sufficient, on average at least 2.56 ± 0.66 cm, spatial distance between tumor and bladder uptake was observed in all cases.CONCLUSIONAn early-imaging protocol in prone position with 68Ga-FAPI-46-PET/CT presents a viable option for non-invasive staging of SCCA and RSC with high TBR and good spatial separation from the urinary bladder.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"15 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144640017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]AlF-NOTA-FAPI-04 PET/CT improves detection of subcentimeter recurrent lesions in differentiated thyroid cancer.","authors":"Kai Zheng,Wanjing Zhou,Jian Yang,Yanyin Zhang,Chengzhi Jiang,Aimin Xie,Xiang Peng,Jiashun Dai,Haifeng He,Xiaowei Peng,Hui Ye","doi":"10.1007/s00259-025-07433-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07433-6","url":null,"abstract":"PURPOSEFibroblast activation protein (FAP)-targeted PET/CT has emerged as a promising tool for visualizing tumor stroma. This study aimed to validate the diagnostic efficacy of [18F]AlF-NOTA-FAPI-04 PET/CT in detecting subclinical metastases in recurrent differentiated thyroid cancer (DTC), with direct comparison to [18F]FDG PET/CT.METHODSTwenty-three DTC participants with biochemical recurrence (suppressed thyroglobulin [Tg] ≥ 1 ng/mL or Tg antibodies [Tg-Ab] > 115 IU/mL) underwent [18F]AlF-NOTA-FAPI-04 PET/CT, including 16 who underwent paired [18F]FDG scans. Lesion classification followed histopathology or 15.5-month clinical follow-up (median, 8-32 months).RESULTS[18F]AlF-NOTA-FAPI-04 PET/CT demonstrated significantly higher lesion-level sensitivity (75% vs. 13%, P = 0.002) and accuracy (80% vs. 27%, P < 0.001) than [18F]FDG. Participant-level sensitivity reached 100% (7/7 vs. 14% [1/7], P = 0.003). Notably, 7 cervical lymph node metastases (mean diameter 5.9 ± 1.4 mm) were detected exclusively by FAPI imaging.CONCLUSION[18F]AlF-NOTA-FAPI-04 PET/CT exhibits superior diagnostic performance over [18F]FDG PET/CT in detecting small metastatic lesions in recurrent DTC, potentially enabling earlier intervention and improved patient management.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"12 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144630254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}